From Earlier: Results from a Randomized Study of REVLIMID and Rituximab in …BenzingaCelgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), announced results from a randomized study comparing REVLIMID® (lenalidomide) plus ri…

'Rediscovered' Lymphoma Drug Helps Double Survival: StudyU.S. News & World ReportThe drug, bendamustine, more than doubled disease progression-free survival when given along with another therapy, rituximab (Rituxan), compared to the drug cockta…

ASCO: Treanda Combo Works in Indolent LymphomasMedPage TodayNote that the bendamustine-rituximab combination had significantly lower rates of a range of adverse events, including hair loss, leukocytopenia, neutropenia, and paresthesias compared with st…

Results from a Randomized Study of REVLIMID® (Lenalidomide) and Rituximab (R2 …EON: Enhanced Online News (press release)BOUDRY, Switzerland–(EON: Enhanced Online News)–Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG)…

Results from a Randomized Study of REVLIMID(R) (Lenalidomide) and Rituximab (R …MarketWatch (press release)Celgene International Sarl, a subsidiary of Celgene Corporation (NASDAQ:CELG) , today announced results from a randomized study comparing REVLI…

UCB to showcase broad immunology portfolio at EULAR 2012MarketWatch (press release)Formal drug interaction studies have not been performed with rituximab or natalizumab; however because of the nature of the adverse events seen with these combinations w…

Can next-generation antibodies offset biosimilar competition?Nature.comPfizer, more recently, has joined Teva, Novartis, Merck & Co. and others in disclosing that it is testing a biosimilar version of Roche's blockbuster anti-CD20 mAb rituximab…

Spectrum Pharmaceuticals Highlights Seven Abstracts of Clinical Data at the …MarketWatch (press release)The ZEVALIN therapeutic regimen consists of two components: rituximab, and Yttrium-90 (Y-90) radiolabeled ZEVALIN for therapy. ZEVALIN builds on t…

Cell Therapeutics' Pixuvri® Phase 3 Clinical Trial Results Published in The …Equities.comThe EMA's Committee for Medicinal Products for Human Use ("CHMP") has accepted PIX306, CTI's ongoing randomized controlled phase 3 clinica…

Cell Therapeutics' Pixuvri® Phase 3 Clinical Trial Results Published in The …MarketWatch (press release)The EMA's Committee for Medicinal Products for Human Use ("CHMP") has accepted PIX306, CTI's ongoing randomized controlled …